Document:

edit_Ex10_30

		
			Exhibit 10.30
		

		
			 
		

		
			Certain identified information has been excluded from the exhibit because it is both (i) not 
		

		
			material and (ii) would likely cause competitive harm to the Company, if publicly disclosed.
		

		
			Double asterisks denote omissions.
		

		
			 
		

		
			November 18, 2019
		

		
			 
		

		
			Editas Medicine, Inc.
		

		
			11 Hurley Street
		

		
			Cambridge, MA 02141
		

		
			Attn.:  Cynthia Collins, CEO
		

		
			 
		

		
			Re: Treating [**] as Co-Exclusive Target; Treatment of Co-Exclusive Targets
		

		
			 
		

		
			Dear Cynthia,
		

		
			 
		

		
			This letter agreement (“Letter Agreement”) is entered into as of the date provided above (the “Effective Date”) by and between, on the one hand, the President and Fellows of Harvard College, an educational and charitable corporation existing under the laws and the constitution of the Commonwealth of Massachusetts, having a place of business at Smith Campus Center, Suite 727, 1350 Massachusetts Avenue, Cambridge, MA 02138 (“Harvard”) and The Broad Institute, Inc., a non-profit Massachusetts corporation, with a principal office at 415 Main Street, Cambridge, MA 02142 (“Broad,” together with Harvard, the “Institutions” and each individually, an  “Institution”) and, on the other hand, Editas Medicine, Inc., a Delaware corporation, with a principal office at 11 Hurley Street, Cambridge, MA 02141 (“Company”). Company and the Institutions are each referred to herein as a “Party” and together, the “Parties.”
		

		
			 
		

		
			Reference is hereby made to (a) that certain Amended and Restated Cas9-I License Agreement by and between, on the one hand, Harvard and Broad and, on the other hand, Company, dated as of October 29, 2014, and amended and restated as of December 16, 2016 (the “Cas9-I Agreement”), (b) that certain Cas9-II License Agreement by and between Broad and Company, dated as of December 16, 2016 (the “Cas9-II Agreement”) and (c) that certain Cpf1 License Agreement by and between Broad and Company, dated as of December 16, 2016 (the “Cpf1 Agreement” and, collectively with the Cas9-I Agreement and the Cas9-II Agreement, the “Agreements” and each individually, an “Agreement”).
		

		
			 
		

		
			The Parties acknowledge that on December 7, 2018, the Company received a Proposed Product Notice for a product directed at the gene target [**] (the “[**] Notice”).  The Institutions desire to have products covered or enabled by the Patent Rights (as defined in each Agreement) developed and commercialized to benefit the public and the Company desires to adjust its obligations with respect to the gene target [**] and the other Co-Exclusive Targets under the Agreements. Therefore, the Parties desire to waive the provisions of Sections 2.6 of the Agreements with respect to the [**] Notice,  designate an additional Co-Exclusive Target under the Agreements and make other adjustments regarding the treatment of Co-Exclusive Targets as set forth herein.
		

		
			 
		

		
			The Parties hereby agree as follows:
		

		
			 
		

		
			1.    Notwithstanding anything to the contrary in the Agreements, as of the Effective Date, [**] shall be added to the schedule of Excluded Targets under each Agreement and shall be deemed to be a Co-Exclusive Target under each Agreement.
		

		
			 
		

		
			 
		

		
			

		 

		

		
			 
		

		
			 
		

		
			2.    Notwithstanding anything to the contrary in the Agreements, solely with respect to Proposed Products for which the Gene Target is a Co-Exclusive Target for which Broad or (solely with respect to the Cas9-I Agreement) Broad and Harvard have granted or have indicated to Company an intention to grant to a Third Party a license under the applicable Patent Rights in the applicable Field, the Quiet Period under each Agreement shall be deemed to be in effect until March 15, 2021. For the avoidance of doubt, the foregoing applies only with respect to the mechanism set forth in Section 2.6 of each Agreement, and does not restrict any other rights of Broad or Harvard under each Agreement, including Broad’s or Broad’s and Harvard’s, as applicable, right to grant a Third Party a license under any of the Patent Rights licensed under any Agreement in the applicable Field with respect to products directed to a Co-Exclusive Target.
		

		
			 
		

		
			3.    Notwithstanding anything to the contrary in the Agreements, following the Effective Date, with respect to running royalties on Net Sales of products, the royalty rates and terms set forth in Exhibit A shall apply in place of the royalty rates and terms set forth in the tables in Section 4.5.1.1 and Section 4.5.1.2 of the Cas9-I and Cas9-II Agreements and Section 4.4.1.1 and Section 4.4.1.2 of the Cpf1 Agreement solely with respect to Licensed Products and Enabled Products under one or more of the Agreements that are (a) products for prevention or treatment of human disease and (b) directed to a Co-Exclusive Target ((a) and (b) collectively “Co-Exclusive Products”).  For clarity, a single royalty based on the rates set forth in Exhibit A shall be due for each Co-Exclusive Product regardless of whether Patent Rights covering such Co-Exclusive Product are licensed under one or more of the Agreements.
		

		
			 
		

		
			4.    Notwithstanding anything to the contrary in the Agreements, following the Effective Date, the royalty offset provisions of Section 4.5.2.1 of the Cas9-I and Cas9-II Agreements and Section 4.4.2.1 of the Cpf1 Agreement shall not apply to any Co-Exclusive Products and Company shall be entitled to offset royalties owed to the Institutions for Co-Exclusive Products as set forth in Section 4.5.2.3 of the Cas9-I and Cas9-II Agreements and Section 4.4.2.3 of the Cpf1 Agreement.
		

		
			 
		

		
			5.    Notwithstanding the foregoing paragraphs 3 and 4, solely with respect to Co-Exclusive Products, on an Agreement-by-Agreement and Co-Exclusive Target-by-Co-Exclusive Target basis, (a) if a Third Party co-exclusive licensee in the Field under the Patent Rights licensed to Company under an Agreement (or such Third Party’s sublicensee under such Patent Rights) publicly discloses that it has initiated a research or development program that uses technology covered by such Patent Rights and is directed to one or more Co-Exclusive Targets (a “Competing Program”), then Company, Broad or, solely in case of the Cas9-I Agreement, Harvard may notify the other party(ies) to this Letter Agreement of such Competing Program or (b) if Company, Broad’s Office of Strategic Alliances and Partnering or, solely in case of the Cas9-I Agreement, Harvard’s Office of Technology Development (the “Informed Party”) receives credible information that such co-exclusive licensee (or its sublicensee) has initiated a Competing Program directed to one or more Co-Exclusive Targets and such Competing Program has not been publicly disclosed, then the Informed Party shall notify the other party(ies) to this Letter Agreement of such Competing Program, in each case subject to the Informed Party’s (and if the Informed Party is Broad’s Office of Strategic Alliances and Partnering, then Broad’s, and if the Informed Party is Harvard’s Office of Technology Development, then Harvard’s) confidentiality obligations to Third Parties (each such notice under the foregoing clauses (a) and (b), a “Competing Program Notice”). Upon a party’s receipt of a Competing Program Notice, (i) the running royalties payable under Exhibit A and the milestones set forth in Sections 4.4.1 and 4.4.2 of the Cas9-I and Cas9-II Agreements and Sections 4.3.1 and 4.3.2 of the Cpf1 Agreement, as applicable, for Co-Exclusive Product(s) directed to the Co-Exclusive Target that is(are) the subject of such Competing Program Notice shall be reduced by [**] percent ([**]%) of the amounts otherwise payable under Exhibit A or
		

		
			
		

		
			

		 

		

			2

		

		

			 

		

		

		
			 
		

		
			Sections 4.4.1 and 4.4.2 of the Cas9-I and Cas9-II Agreements and Sections 4.3.1 and 4.3.2 of the Cpf1 Agreement,  as applicable, during the applicable Competing Program Term (as defined below), and (ii) if Company has made running royalty or milestone payments under the applicable Agreement with respect to such Co-Exclusive Products prior to the receipt of such Competing Program Notice, then Company shall be entitled to offset the foregoing deduction against future royalties or milestones payable under such Agreement with respect to such Co-Exclusive Products, as applicable, during the applicable Competing Program Term, subject to the terms of paragraph 6 below. Disputes arising under this paragraph 5 shall be referred to the Executive Officers pursuant to the Dispute resolution section of the applicable Agreement, and there shall be no reduction in royalties or milestones or credit pursuant to this paragraph 5 during the pendency of any such dispute.
		

		
			 
		

		
			“Competing Program Term” means, with respect to a Competing Program, the period beginning on the date of a party’s receipt of the applicable Competing Program Notice and ending upon the earlier of the following: (a) the date on which the applicable Third Party publicly discloses that such Competing Program has ended, (b) the date on which an Informed Party receives credible information that such Competing Program has ended or (c) the date on which the applicable Third Party becomes an Affiliate of Company. In the event that Company is the “Informed Party” under the foregoing clause (b), Company shall promptly notify Broad and, if applicable, Harvard of the applicable credible information described in the foregoing clause (b).
		

		
			 
		

		
			6.    Notwithstanding anything to the contrary in the Agreements or this Letter Agreement, on an Agreement-by-Agreement and product-by-product basis, at any time when Company is entitled to offset the running royalty payments payable under Exhibit A,  with respect to a Co-Exclusive Product under both paragraph 5 above and any other royalty offset provision in an Agreement, in no event shall running royalty payments for such Co-Exclusive Product under Exhibit A be reduced such that Broad receives (or the Institutions or Payee Institutions receive, as applicable) running royalty payments at less than [**] percent ([**]%) of the applicable royalty rate set forth in Exhibit A.
		

		
			 
		

		
			7.    In addition to the obligations set forth in Sections 11.3 of the Agreements, the Parties hereby agree that any public statement or press release issued by a Party regarding or mentioning the Co-Exclusive Targets shall (i) refer to the rights licensed by the Institutions with respect to such targets as co-exclusive under the Agreements and (ii) in no way represent that the Parties followed the Inclusive Innovation Model procedures as set forth in Sections 2.6 of the Agreements with regard to the gene target [**], unless the other Party has provided prior written approval otherwise after the Effective Date.
		

		
			 
		

		
			8.    The Parties agree that, as of the Effective Date, all requirements, rights and obligations under Sections 2.6 of the Agreements with respect to the [**] Notice are hereby permanently and irrevocably waived.
		

		
			 
		

		
			9.    All capitalized terms used herein and not otherwise defined shall have the meaning given to them in the applicable Agreement.
		

		
			 
		

		
			10.  Except as explicitly set forth in this Letter Agreement, the Agreements remain unchanged and their terms and conditions and the rights and obligations of the Parties thereunder remain in full force and effect.
		

		
			 
		

		
			11.  Except as otherwise set forth herein, this Letter Agreement may not be amended, waived or terminated without the written consent of both the Licensor Institutions and Company.
		

		
			 
		

		
			
		

		
			

		 

		

			3

		

		

			 

		

		

		
			 
		

		
			12.  This Letter Agreement may not be assigned except in connection with an assignment of an Agreement in accordance with the terms thereof and solely with respect to the rights and obligations herein that relate to such Agreement.
		

		
			 
		

		
			13.  This Letter Agreement shall be governed by, and construed in accordance with, the substantive laws of the Commonwealth of Massachusetts, without giving effect to any choice or conflict of law provision.
		

		
			 
		

		
			14.  This Letter Agreement may be executed in three or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Once signed, any reproduction of this Letter Agreement made by reliable means (e.g., pdf, photocopy, facsimile) shall be considered an original.
		

		
			 
		

		
			(Signature Page Follows)
		

		
			 
		

		
			 
		

		
			

		 

		

			4

		

		

			 

		

		

		
			 
		

			
					
						Sincerely,

					
					
						    

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						/s/ Jesse Souweine

				
	
					
						 

					
					
						 

					
					
						Jesse Souweine

				
	
					
						 

					
					
						 

					
					
						Chief Operating Officer

				
	
					
						 

					
					
						 

					
					
						The Broad Institute, Inc.

				

		
			 
		

		
			 
		

			
					
						 

					
					
						    

					
					
						/s/ Isaac T. Kohlberg

				
	
					
						 

					
					
						 

					
					
						Isaac T. Kohlberg

				
	
					
						 

					
					
						 

					
					
						Senior Associate Provost and

				
	
					
						 

					
					
						 

					
					
						Chief Technology Development Officer

				
	
					
						 

					
					
						 

					
					
						Harvard University

				

		
			 
		

		
			 
		

			
					
						Acknowledged and Agreed:

					
					
						    

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						/s/ Cynthia Collins

					
					
						 

					
					
						 

				
	
					
						Cynthia Collins

					
					
						 

					
					
						 

				
	
					
						Chief Executive Officer

					
					
						 

					
					
						 

				
	
					
						Editas Medicine, Inc.

					
					
						 

					
					
						 

				

		
			 
		

		
			
		

		
			

		 

		

			 

		

		

		
			EXHIBIT A
		

		
			 
		

		
			Royalty rates under the Agreements that are solely applicable to Licensed Products and Enabled Products that are (a) products for the prevention or treatment of human disease and (b) directed to a Co-Exclusive Target:
		

		
			 
		

		
			Licensed Products
		

		
			 
		

			
					
						Royalty Tiers

					
					
						Royalty Rate

				
	
					
						The portion of aggregate annual Net Sales up to and including [**] dollars ($[**])

					
						 

					
					
						[**]% of Net Sales by Company, its Affiliates, and Sublicensees

				
	
					
						The portion of aggregate annual Net Sales greater than [**] dollars ($[**]) and less than [**] dollars ($[**])

					
						 

					
					
						[**]% of Net Sales by Company, its Affiliates, and Sublicensees

				
	
					
						The portion of aggregate annual Net Sales greater than [**] dollars ($[**])

					
						 

					
					
						[**]% of Net Sales by Company, its Affiliates, and Sublicensees

				

		
			 
		

		
			Enabled Products
		

		
			 
		

			
					
						Royalty Tiers

					
					
						Royalty Rate

				
	
					
						The portion of aggregate annual Net Sales up to and including [**] dollars ($[**])

					
						 

					
					
						[**]% of Net Sales by Company, its Affiliates, and Sublicensees

				
	
					
						The portion of aggregate annual Net Sales greater than [**] dollars ($[**]) and less than [**] dollars ($[**])

					
						 

					
					
						[**]% of Net Sales by Company, its Affiliates, and Sublicensees

				
	
					
						The portion of aggregate annual Net Sales greater than [**] dollars ($[**])

					
						 

					
					
						[**]% of Net Sales by Company, its Affiliates, and Sublicensees

				

		
			 
		

		
			Adjustment for Group B Licensed Products and Group B Enabled Products: The above royalty rates shall be reduced by [**] percent ([**]%) for applicable products that both (i) are Group B Licensed Products or Group B Enabled Products under the Cas9-II Agreement and (ii) are not also Licensed Products or Enabled Products under the Cas9-I Agreement or Cpf1 Agreement, pursuant to the terms set forth in Section 4.5.1.3 of the Cas9-II Agreement.edit_Ex10_31

			

					

						

					

					

						11 Hurley Street

				
	

					

						Cambridge, MA 02141

				
	

					

						P 617-401-9000

				
	

					

						F 617-494-0985

				

		

			 

		

		

			Exhibit 10.31

		

		

			 

		

		
			Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed.  Double asterisks denote omissions.
		

		
			CONFIDENTIAL
		

		
			December 16, 2019
		

		
			The Broad Institute, Inc.
		

		
			415 Main Street
		

		
			Cambridge, MA  02142
		

		
			Attn: Issi Rozen, Chief Business Officer
		

		
			Office of Technology Development
		

		
			Harvard University
		

		
			Richard A. and Susan F. Smith Campus Center, Suite 727
		

		
			1350 Massachusetts Avenue
		

		
			Cambridge, MA  02138
		

		
			Attn.: Isaac Kohlberg, Chief Technology Development Officer
		

		
			Re:Amended and Restated Cas9‐I License Agreement, by and between President and Fellows of Harvard College (“Harvard”), The Broad Institute, Inc. (“Broad”) and Editas Medicine, Inc. (“Editas”), dated October 29, 2014, and amended and restated as of December 16, 2016 (as amended, the “Cas9‐I Agreement”); Cpf1 License Agreement, by and between Broad and Editas, dated December 16, 2016 (the “Cpf1 Agreement”); and Cas9‐II License Agreement, by and between Broad and Editas, dated December 16, 2016 (the “Cas9‐II Agreement” and collectively, with the Cas9‐I Agreement and the Cpf1 Agreement, each as may be amended and/or restated from time to time, the “License Agreements”) –  Sublicense Income
		

		
			Dear Issi and Isaac,
		

		
			The purpose of this letter (the “Letter”) is to memorialize certain understandings among Harvard, Broad, and Editas as to certain provisions of the License Agreements regarding sublicensing income. All capitalized terms used in this Letter that are not defined in this Letter shall have their respective meanings as set forth in the License Agreements.
		

		
			Flow Through of Financial Obligations in Sublicense Agreements
		

		
			Harvard and Broad each hereby acknowledges and agrees that if (A) Editas sublicenses or has sublicensed any of the rights licensed to Editas under any of the License Agreements to a third party, (B) the applicable Sublicense includes milestone payment obligation(s) that are triggered by the achievement of milestone(s) based on objective criteria that are materially similar as a  Milestone Event(s) criteria for Milestone Payment(s) under an applicable License Agreement or such Milestone Payment obligation(s) under an applicable License Agreement are flowed through to the applicable Sublicensee (each, a  “Comparable Milestone”),  (C) such Sublicense includes payment obligation(s) with respect to such Comparable Milestones requiring the Sublicensee to make a milestone payment to Editas or a Milestone Payment(s) to Harvard and/or Broad, as required under the applicable License Agreements, either directly or through Editas and (D) such Comparable 

		 

		

			 

		

		

			 

		

		

			

		

Milestone(s) are achieved and the Sublicensee either pays Broad and/or Harvard (as applicable) directly or pays Editas or one of its Affiliates and Editas pays Broad and/or Harvard (as applicable) for the applicable Milestone Payment(s) (the “Sublicense Milestone Payment”), then Editas shall not be required to pay the portion of Sublicense Income that may otherwise be deemed to arise from the Sublicense Milestone Payment to the extent the Sublicense Milestone Payment is either (I) paid directly to Harvard and/or Broad or (II) received by Editas or its Affiliate and Editas pays Broad and/or Harvard (as applicable) for the applicable Milestone Payment(s).  For illustrative purposes of clause (B) of the prior sentence, the [**] would be materially similar to the [**].  For clarity, Editas would remain obligated to pay Harvard and/or Broad the applicable portion of Sublicense Income arising from any portion of a Sublicense Milestone Payment that exceeds the comparable Milestone Payment under the applicable License Agreement.  For further clarity, in the event there are Sublicense Milestone Payments under more than one Sublicense for the same Comparable Milestone and the same product or service that is triggering such Comparable Milestone, this exclusion of the Sublicense Milestone Payments from Sublicense Income may only be taken up to the total amount of the Milestone Payment, in the aggregate, owed to Harvard and/or Broad with respect to such Comparable Milestone.  For example, if Editas sublicenses rights under the Cas9‐I Agreement to a Sublicensee and such Sublicense includes a milestone requiring the sublicensee to pay Editas $75,000 upon [**]  (which is a Comparable Milestone as to a Milestone Event under the Cas9‐I Agreement, and under the Cas9‐I Agreement such Milestone Event triggers a $60,000 Milestone Payment obligation of Editas to Harvard and Broad), then Editas would be required to pay Broad and Harvard, in accordance with the applicable allocation of consideration provision in the Cas9‐I Agreement,  (x) $60,000 for the achievement of such Milestone Event, plus (y) the applicable Sublicense Income rate  (for purposes of this example, assume that the applicable rate is 15%) multiplied by the incremental $15,000 of such Sublicense Milestone Payment that exceeds $60,000, or $2,250, that Editas or its Affiliate receives from the such Sublicensee in connection with the achievement of the Comparable Milestone for a total payment of $62,250.  In the foregoing example, Editas would not be required to pay an additional 15% of the first $60,000 of the $75,000 Sublicense Milestone Payment as a Sublicense Income payment.
		

		
			Additionally, Harvard and Broad each hereby acknowledge and agree that if Editas includes or has included payment obligations in a Sublicense that specifically require a Sublicensee to pay all or a portion of the annual license maintenance fees and/or patent reimbursement costs that, in each case, Editas is required to pay to Harvard and/or Broad with respect to such fees or costs under any of the License Agreements, then Editas shall not be required to pay to Broad and/or Harvard the portion of Sublicense Income that may otherwise be deemed to arise from such fees or costs paid by such sublicensee (I) to the extent such payments are equal to or less than the amounts owed by Editas to Broad and Harvard under the applicable License Agreement, (II) such payments are actually paid to Broad and Harvard, and (III) in the event such payments are required under more than one Sublicense for the same requirement under the applicable License Agreements, this exclusion from Sublicense Income may only be taken to the extent Editas or its sublicensee pays Harvard and/or Broad such fees, e.g. if a License Agreement has annual fees of $100,000 and Editas has two Sublicenses under which Editas receives a total of $150,000 and pays Harvard and/or Broad $100,000 for such annual fee therefrom, Editas will still have $50,000 of Sublicense Income.
		

		
			Sublicense Income and Reimbursement of Future Patent Expenses and Allocated Past Patent Expenses
		

		
			Each of Editas, Harvard and Broad acknowledges and agrees that, on a License Agreement-by-License Agreement basis, in the event Editas enters into or has entered into a Sublicense and Editas or any of its Affiliates receives any Sublicense Income and there is no specific allocation as to such Sublicense Income in such Sublicense with respect to reimbursement for patent costs, then Editas shall be entitled to deduct from such Sublicense Income received by Editas after the date of this Letter any amounts paid to Broad or Harvard, respectively, under the applicable License Agreements, as reimbursement of patent costs incurred by Broad or Harvard after the date of this Letter with respect to rights licensed to Editas under such License Agreements to 

		 

		

			2

		

		

			

		

the extent not previously deducted and provided that no such deduction shall reduce the amount of such Sublicense Income by greater than [**] percent  ([**]%) of what it would have been absent such deduction.
		

		
			Each of Editas, Harvard and Broad acknowledges and agrees that, on a License Agreement-by-License Agreement basis, in the event Editas enters into or has entered into a Sublicense and Editas or any of its Affiliates receives any Sublicense Income and there is a specific allocation as to such Sublicense Income in such Sublicense with respect to reimbursement for patent costs, then Editas shall be entitled to deduct such specifically-allocated amount from such Sublicense Income received by Editas after the date of this Letter to the extent not previously deducted the amounts paid to Broad or Harvard, respectively, under the applicable License Agreements as reimbursement of patent costs incurred by Broad or Harvard in accordance with such allocation, regardless of whether Broad or Harvard incurred such fees prior to or after the date of this Letter.
		

		
			We request that an authorized signatory on behalf of Harvard and Broad kindly sign a copy of this Letter acknowledging receipt of this Letter and the acceptance of the terms contemplated hereby.
		

		
			Please contact me if you have any questions.
		

		
			Sincerely,
		

			
					
						EDITAS MEDICINE, INC.

				
	
					
						 

					
					
						 

				
	
					
						By:

					
					
						/s/ Cynthia Collins

					
					
						 

				
	
					
						Name:

					
					
						 Cynthia Collins

				
	
					
						Title: 

					
					
						Chief Executive Officer

				
	
					
						Date: December 16, 2019

				
	
					
						 

					
					
						 

				
	
					
						Acknowledged and agreed by:

				
	
					
						 

					
					
						 

				
	
					
						THE BROAD INSTITUTE, INC.

				
	
					
						 

					
					
						 

				
	
					
						By:

					
					
						 /s/ Issi Rozen

					
					
						 

				
	
					
						Name: 

					
					
						Issi Rozen

				
	
					
						Title: 

					
					
						CBO

				
	
					
						Date: December 17, 2019

				
	
					
						 

					
					
						 

				
	
					
						PRESIDENT AND FELLOWS OF HARVARD COLLEGE

				
	
					
						 

					
					
						 

				
	
					
						By: 

					
					
						/s/ Isaac T. Kohlberg

					
					
						 

				
	
					
						Name:

					
					
						Isaac T. Kohlberg

				
	
					
						Title:

					
					
						Senior Associate Provost, Chief Technology Development Officer; Office of Technology Development, Harvard University

				
	
					
						Date: December 17, 2019

				

		
			 
		

		 

		

			3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00305-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00305-of-00352.parquet"}]]